I
Isabelle Koné-Paut
Researcher at University of Paris-Sud
Publications - 289
Citations - 13141
Isabelle Koné-Paut is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Medicine & Familial Mediterranean fever. The author has an hindex of 55, co-authored 260 publications receiving 10637 citations. Previous affiliations of Isabelle Koné-Paut include University of Paris & Versailles Saint-Quentin-en-Yvelines University.
Papers
More filters
Journal ArticleDOI
Use of canakinumab in the cryopyrin-associated periodic syndrome.
Helen J. Lachmann,Isabelle Koné-Paut,Jasmin B Kuemmerle-Deschner,Kieron S. Leslie,Eric Hachulla,Pierre Quartier,Xavier Gitton,A Widmer,N Patel,Philip N. Hawkins +9 more
TL;DR: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS and evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA).
Journal ArticleDOI
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
Nicolino Ruperto,Hermine I. Brunner,Pierre Quartier,Tamás Constantin,Nico M Wulffraat,Gerd Horneff,Riva Brik,Liza J McCann,Ozgur Kasapcopur,Lidia Rutkowska-Sak,Rayfel Schneider,Yackov Berkun,Inmaculada Calvo,Muferet Erguven,Laurence Goffin,Michael Hofer,Tilmann Kallinich,Sheila Knupp Feitosa de Oliveira,Yosef Uziel,Stefania Viola,Kiran Nistala,Carine Wouters,Rolando Cimaz,Manuel A. Ferrandiz,Berit Flatø,M.L. Gamir,Isabelle Koné-Paut,Alexei A. Grom,Bo Magnusson,Seza Ozen,Flavio Sztajnbok,Karine Lheritier,Ken Abrams,Dennis Y. Kim,Alberto Martini,Alberto Martini,Daniel J. Lovell +36 more
TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.
Journal ArticleDOI
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.
Marie Pouletty,Charlotte Borocco,Naim Ouldali,Marion Caseris,Romain Basmaci,Noémie Lachaume,Philippe Bensaid,Samia Pichard,Hanane Kouider,Guillaume Morelle,Irina Craiu,Corinne Pondarré,Anna Deho,Arielle Maroni,Mehdi Oualha,Zahir Amoura,Julien Haroche,Juliette Chommeloux,Fanny Bajolle,Constance Beyler,Stéphane Bonacorsi,Guislaine Carcelain,Isabelle Koné-Paut,Brigitte Bader-Meunier,Albert Faye,Ulrich Meinzer,Caroline Galeotti,Isabelle Melki +27 more
TL;DR: Kawa-COVID-19 likely represents a new systemic inflammatory syndrome temporally associated with SARS-CoV-2 infection in children, and further prospective international studies are necessary to confirm these findings and better understand the pathophysiology of Kawa- CO VID-19.
Journal ArticleDOI
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France
Thierry Lequerré,Pierre Quartier,D Rosellini,F Alaoui,M. De Bandt,O. Mejjad,Isabelle Koné-Paut,Marc Michel,Emmanuelle Dernis,Mehdi Khellaf,Nicolas Limal,Chantal Job-Deslandre,Bruno Fautrel,X. Le Loët,J. Sibilia,Club Rhumatismes et Inflammation +15 more
TL;DR: Anakinra was effective in most AoSD patients, but less than half SoJIA patients achieved a marked and sustained improvement.
Journal ArticleDOI
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
Pierre Quartier,Pierre Taupin,Franck Bourdeaut,Irène Lemelle,Pascal Pillet,Michel Bost,Jean Sibilia,Isabelle Koné-Paut,Sylvie Gandon-Laloum,Marc LeBideau,Brigitte Bader-Meunier,Richard Mouy,Marianne Debré,Paul Landais,Anne-Marie Prieur +14 more
TL;DR: Although most patients initially respond to etanercept, this initial response is not always followed by sustained improvement over longer periods of time, and the higher rate of treatment failure in the group with systemic-onset JIA indicates that these patients in particular may require alternative treatments.